404 related articles for article (PubMed ID: 25851862)
21. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
[TBL] [Abstract][Full Text] [Related]
22. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
23. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
[TBL] [Abstract][Full Text] [Related]
25. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
[TBL] [Abstract][Full Text] [Related]
26. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
28. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
30. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
31. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Plasma Cytokine Profile Changes in Bevacizumab-Treated Retinopathy of Prematurity Infants.
Kong L; Demny AB; Sajjad A; Bhatt AR; Devaraj S
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1649-54. PubMed ID: 27054517
[TBL] [Abstract][Full Text] [Related]
33. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
[TBL] [Abstract][Full Text] [Related]
34. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
[TBL] [Abstract][Full Text] [Related]
35. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
[TBL] [Abstract][Full Text] [Related]
36. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
37. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
[TBL] [Abstract][Full Text] [Related]
38. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
VanderVeen DK; Cataltepe SU
Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
[TBL] [Abstract][Full Text] [Related]
39. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
[No Abstract] [Full Text] [Related]
40. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
Sukgen EA; Koçluk Y
Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
